Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (August 2015)
42 slides from Sorrento Therapeutics's investor presentation, August 2015
Slide 1: Corporate Presentation
Therapeutics Corporate Presentation Henry Ji, PhD - President and CEO © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.
Slide 2: Disclaimer
Disclaimer NASDAQ: SRNE Certain statements contained in this presentation or in other documents of In presenting this material or responding to inquiries in connection with a Sorrento Therapeutics, Inc. (the “Company”), along with certain statements presentation, management may refer to results, pro
Slide 3: Sorrento and NantWorks Alliances
Cellu Immuno-O Intralar Bis ncol N p ogy ec - AD ific Na Cs nt s nse Antibodies A ce ll Li Onc Ce Ce Na nt olog ll V y ody J N TiB NAN Bio Na ience Sc V rStemCell J nt NantCance T Biologics Autoimmune Sorrento NantWorks Pharma NantPaclitaxel Nant Inflammation Alliances W Therapeutics Major Share i P
Slide 4: Pipeline
Pipeline Code Target Preclinical Phase I Phase II Phase III STI-001 EGFR STI-002 TNF-α STI-003 CD25 mAbs STI-004 IgE STI-1014 PD-L1 STI-1110 PD1 CAR-T CEA CAR-T PSMA CAR-T CAR-T GD3 CAR-T IL13R CAR-T c-KIT CAR.TNK PD-L1 CAR.TNK CAR.TNK ROR1 Resiniferatoxin RTX TRPV1 ** Partnered with NantKwest * Com
Slide 5: NantWorks Affiliates
NANTWORKS Entity / Transaction Assets Economics / Value Affiliates Immunotherapy 1 x Phase 3 mAb 40% equity in JV NANTiBody JV Pre-specified GMABs $100M JV capitalization NantCell Neo-epitope GMABs $100M equity in NantCell License 2 CAR.TNKs S10M license fee + future royalties Pre-specified GMABs Ta
Slide 6: Immunotherapy Platform
Immunotherapy Platform © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 6
Slide 7: G-MAB Library
G-MAB Library Highly Successful Screening Hit Rate Fully Human Antibodies (100+ targets screened) Proprietary Technology Very High Diversity RNA amplification used for library generation 2.1 x 1016 Distinct Antibodies Difficult Targets High Value Oncology Targets Most Difficult Targets: Small Peptid
Slide 8: Sorrento Immunotherapy Platform
Sorrento Immunotherapy Platform ADCs Antibody Drug Conjugates Proprietary Toxins Intracellular c-MET Conjugation Chemistries Targets Adoptive Immunotherapy PD-L1 Bispecific Abs Secreted Chemical BsAb (CBAs) Targets IgG-based Proprietary Biochemistry CAR.TNK CAR-T © 2015, Sorrento Therapeutics, Inc.
Slide 9: In Vivo Synergy of Anti-PD-L1 mAb with Clinical HSP90 Inhibitor
In Vivo Synergy of Anti-PD-L1 mAb with Clinical HSP90 Inhibitor 2000 C57 BL/6 mice bearing MC38 colon carcinomas (n = 7/group) were treated with 200 μg IgG1 control or the anti-PD-L1 antibody STI-A1015 (dosed on day 8, 12 Average tumor volume (mm3) 1500 IgG1 ,and 15), either alone or in combination
Slide 10: PD-L1 c-MET Bispecific Antibodies
Bispecific Antibodies c-MET PD-L 1 - L1 PD EGFR © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 10
Slide 11: Chemically-Generated Bispecific Antibodies (CBA) Technology
Chemically-Generated Bispecific Antibodies (CBA) Technology Antibody 1 Antibody 2 1. Reduction 1. Reduction 2. Linker Conjugation 2. Linker Conjugation s Linker - A B-Linker s s s Orthogonal Conjugation s s s s © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 11
Slide 12: Functional Activity of Chemically-generated Bispecific Abs (CBA)
Functional Activity of Chemically-generated Bispecific Abs (CBA) Binding to MDA-MB-231 cells Anti-PD-L1 activity of CBA Anti-c-Met activity of CBA (TNBC cell line) 15000 0.30 CBA IL-2 concentration (pg/mL) 1500 STI-A1015 0.25 1000 anti PD-L1 mAb CBA Control IgG OD (450 nM) MFI (FL4) 0.20 STI-A1010 S
Slide 13: Concortis/Sorrento Enabling ADC Technologies
Concortis/Sorrento Enabling ADC Technologies Highly Potent Proprietary Payloads Duostatins™ (Tubulin inhibitors) Duomycins™ (DNA alkylating agents) New MOA payloads c-MET Site-specific Conjugation Methods K-Lock™ C-Lock™ Powerful Screening Panels From antibody to ADC leads in 2 months Optimized comb
Slide 14: cMET ADCs Exhibits Potent Antitumor Activity
cMET ADCs Exhibits Potent Antitumor Activity In H292 and EBC-1 NSCLC Xenograft Models H292 (c-Met ++) EBC-1 (c-Met +++) Vehicle Vehicle Tumor Volume (nm3) 2500 2500 2000 2000 c-Met 0174 Mean +SEM (1mg/kg) 1500 1500 c-Met 0174 1000 1000 (3mg/kg) c-Met 0174 (3mg/kg) 500 ** 500 c-Met 0174 ** (10mg/kg)
Slide 15: BioSimilars
BioSimilars © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 15
Slide 16: STI-001 BioSimilar / BioBetter mAb to Cetuximab
STI-001 BioSimilar / BioBetter mAb to Cetuximab Cetuximab – Eli Lilly/BMS/Merck KGaA Backgrounds Chimeric monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR) Binding of Erbitux to EGFR interferes with ligand-mediated activation of the receptor’s
Slide 17: STI-002 BioSimilar / BioBetter mAb to Infliximab
STI-002 BioSimilar / BioBetter mAb to Infliximab Remicade INFLIXIMAB Infliximab – Janssen Backgrounds Chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α) Approvals / Crohn’s Disease, pediatric Crohn’s Disease, Ulcerative Collitis, pediatric Ulcerative Collitis, Indications Rheu
Slide 18: STI-003 BioSimilar / BioBetter mAb to Basiliximab
STI-003 BioSimilar / BioBetter mAb to Basiliximab Basiliximab – Novartis1 basiliximab Backgrounds Chimeric monoclonal antibody (IgG1k ) that binds to and blocks the binding of IL-2 to IL-2Ra (aka CD25) on the surface of activated T-lymphocytes. This specific, high affinity binding to IL-2Ra competit
Slide 19: STI-004 BioSimilar mAb to Omalizumab
STI-004 BioSimilar mAb to Omalizumab Omalizumab – Novartis/Genentech Backgrounds Xolair (omalizumab; Roche/Novartis), a humanized monoclonal antibody product, inactivates immunoglobulin E (IgE), preventing the inflammatory events that lead to asthma exacerbations. Omalizumab inhibits the binding of
Slide 20: Harnessing Adaptive and Innate Immunity
Harnessing T Cell Adaptive and Innate NK92 Immunity © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 20
Slide 21: Synergistic Effect CAR-T & CAR.TNK
Synergistic Effect CAR-T CAR.TNK CAR-T & CAR.TNK Delayed killing Rapid killing CAR-T cell proliferation Repeated dosing Persistent effect via engraftment Transient effect due to irradiation © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 21
Slide 22: G-MAB CAR-T and CAR.TNK
G-MAB Library Clinical stage programs for solid tumors Chimeric Antigen Receptor (CAR)-based Immunotherapies harnessing: CAR-T and CAR.TNK • T-cell immunity with CAR-T therapy (autologous) • Natural Killer cell immunity with CAR.TNK therapy (off-the-shelf ) Granzyme Multi-pronged strategy to increas
Slide 23: Positioning
Positioning T-cells NK Natural Killer cells CAR-T CAR.TNK © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 23
Slide 24: Therapeutic Platform
Therapeutic Platform CAR-T Programs G-MAB CAR.TNK Technology Acquisition CAR-T NK92 Fully human antibody library © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 24
Slide 25: Autologous CAR-T Manufacturing
Autologous CAR-T Manufacturing Leukapheresis PBMC collection T-cell activation (Peripheral Blood Mononuclear Cells) (CD3 antibody + cytokines) CAR-T Infusion CAR-T CAR-T Cell Expansion Viral Transduction Drug Product © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 25
Slide 26: CEA CAR-T in Metastatic Liver Cancer Patients
CEA CAR-T in Metastatic Liver Cancer Patients 100% #4 #8 80% #6 Survival 60% #7 40% #1 20% #5 0% 0 20 40 60 80 100 Weeks Source: Clin Cancer Res. 2015 Jul 15: 21(14): 3149-59 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 26
Slide 27: IL13 CAR-T: Inhibition of Tumor Growth of Xenograft Glioma
IL13 CAR-T: Inhibition of Tumor Growth of Xenograft Glioma 100% 80% Tumor + Survival 60% IL13 CAR-T cells (n=11) 40% Tumor + 20% Tumor only Untransduced T Cells (n=10) (n=4) 0% 0 20 40 60 80 100 120 Days Source: Kong et al. Clin Cancer Res. 18(21):5949-60, 2012 © 2015, Sorrento Therapeutics, Inc. AL
Slide 28: CAR.TNK cGMP Manufacturing Process
CAR.TNK cGMP Manufacturing Process Off-the-shelf Drug Product BioReactor Electroporation cell expansion or NK92 CAR.TNK Viral Transduction CAR.TNK CAR.TNK cGMP CAR.TNK Manufacturing CAR © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 28
Slide 29: HER2.TNK in Glioma Model
HER2.TNK in Glioma Model Survival 100 (%) p<0.01 80 272 Days 60 40 20 Medium NK92 CAR.TNK Days 80 120 160 200 240 280 Source: Schönfeld et al., Mol Ther. 23(2):330-8, 2015 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 29
Slide 30: Diagnostic Platform
Diagnostic Platform CTC G-MAB (Circulating Tumor Cells) CTC Panel for Cancer Patients PD-L1 CEA GD3 ROR1 Exclusive License for Fully human CD123 cell-based therapies antibody library © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 30
Slide 31: Cytolumina: Circulating Tumor Cell (CTC) Profiling Technology
Cytolumina: Circulating Tumor Cell (CTC) Profiling Technology TUMOR Blood Vessel CTCs in circulation PD-L1 CEA CTCs detected and profiled CTCs captured by NanoVelcro Chip Source: Cytolumina Data © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 31
Slide 32: Precision Medicine
Precision Medicine Diagnostic Patients Profiling Treatment & Maintenance Hospital CARs CAR Selection CAR-T / CAR.TNK © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 32
Slide 33: Combination Immunotherapy
Combination Immunotherapy CAR-Based CAR-T mAb Therapy Small Molecule CAR.TNK © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 33
Slide 34: Pain Franchise
Pain Franchise © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 34
Slide 35: RTX Target Product Profile
RTX Target Product Profile Mechanism of Action Efficacy Ultrapotent, highly-specific TRPV1 Meaningful analgesia with agonist that selectively ablates concomitant opioid reduction and afferent neurons (“molecular improvement in function neurolysis”) Safety Dosing Alteration of heat sensation in Targe
Slide 36: Two Injection Sites = Two Products for Human Use
Two Injection Sites = Two Products for Human Use Dorsal Root Dorsal Horn Epidural injection Dorsal Root Ganglion (DRG) into or near dorsal root ganglion (DRG) for unilateral or diffuse pain Intrathecal injection into cerebrospinal fluid space (CSF) Ventral Horn targeting both DRGs and dorsal horn ne
Slide 37: Scintilla: Human Pipeline
Scintilla: Human Pipeline 1 Refractory Cancer Pain Intrathecal injection into the CFS targeting both DRG and dorsal horn neurons 2 Spinal Cord Injury Pain 3 Chronic Phantom Limb Pain Epidural injection into or near the DRG for unilateral or diffuse pain 4 Cancer-Induced Bone Pain © 2015, Sorrento Th
Slide 38: RTX: Results from First-In-Human Study
RTX: Results from First-In-Human Study • Improved pain and increased activity with reduced opioid utilization • No unexpected toxicities • MTD not reached with 1 mL RTX over 2 min via infusion pump • 3 non or poorly ambulatory patients able to 12 patients with advanced cancer become ambulatory (43-6
Slide 39: Reduced Spread = Broader Therapeutic Window
Reduced Spread = Broader Therapeutic Window Post RTX Treatment Post RTX Treatment No pain day after RTX, by day 28 most Substantial pain reduction from 7-10/10 days are at “0” pain with some days up to 0-4/10 by day 14 to 6-7/10 Uses breakthrough pain meds only Opioid utilization reduced by about oc
Slide 40: ARK's Pipeline: Multiple Products from 2 API's
ARK’s Pipeline: Multiple Products from 2 API’s Pyoderma, Ark-005 Cancer pain, Ark-001 Idiopathic cystitis, Ark-003 Ocular abrasion, Ark-004 Neuropathic pain, Ark-002 Mastitis, Ark-006 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED. 40
Slide 41: Sorrento and NantWorks Alliances
Cellu Immuno-O Intralar Bis ncol N p ogy ec - AD ific Na Cs nt s nse Antibodies A ce ll Li Onc Ce Ce Na nt olog ll V y ody J N TiB NAN Bio Na ience Sc V rStemCell J nt NantCance T Biologics Autoimmune Sorrento NantWorks Pharma NantPaclitaxel Nant Inflammation Alliances W Therapeutics Major Share i P
Slide 42: Contact
Therapeutics Contact Henry Ji, PhD - President and CEO hji@sorrentotherapeutics.com (858) 668-6923 42
Sorrento Therapeutics — Investor Presentation (August 2015) on 6ix